Mark Sheptoff Financial Planning’s Flexion Therapeutics, Inc. FLXN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-1,000
| Closed | -$6K | – | 484 |
|
|
2021
Q3 | $6K | Hold |
1,000
| – | – | ﹤0.01% | 342 |
|
|
2021
Q2 | $8K | Hold |
1,000
| – | – | ﹤0.01% | 346 |
|
|
2021
Q1 | $9K | Hold |
1,000
| – | – | 0.01% | 298 |
|
|
2020
Q4 | $12K | Buy |
1,000
+500
| +100% | +$5.81K | 0.01% | 262 |
|
|
2020
Q3 | $5K | Hold |
500
| – | – | ﹤0.01% | 275 |
|
|
2020
Q2 | $7K | Hold |
500
| – | – | ﹤0.01% | 283 |
|
|
2020
Q1 | $4K | Sell |
500
-200
| -29% | -$3.01K | ﹤0.01% | 291 |
|
|
2019
Q4 | $14K | Hold |
700
| – | – | 0.01% | 256 |
|
|
2019
Q3 | $10K | Hold |
700
| – | – | 0.01% | 274 |
|
|
2019
Q2 | $9K | Hold |
700
| – | – | 0.01% | 274 |
|
|
2019
Q1 | $9K | Buy |
700
+200
| +40% | +$2.67K | 0.01% | 275 |
|
|
2018
Q4 | $6K | Sell |
500
-1,700
| -77% | -$26.7K | 0.01% | 276 |
|
|
2018
Q3 | $41K | Hold |
2,200
| – | – | 0.03% | 185 |
|
|
2018
Q2 | $57K | Hold |
2,200
| – | – | 0.04% | 148 |
|
|
2018
Q1 | $49K | Buy |
2,200
+900
| +69% | +$22K | 0.03% | 161 |
|
|
2017
Q4 | $33K | Buy |
1,300
+200
| +18% | +$4.9K | 0.02% | 204 |
|
|
2017
Q3 | $27K | Hold |
1,100
| – | – | 0.02% | 217 |
|
|
2017
Q2 | $22K | Buy |
+1,100
| New | +$22.9K | 0.02% | 222 |
|
Mark Sheptoff Financial Planning's FLXN Position: Q4 2021 in Review
Mark Sheptoff Financial Planning sold out of Flexion Therapeutics, Inc. (FLXN) in Q4 2021, closing a stake of 1,000 shares — an estimated $6K sold.
Mark Sheptoff Financial Planning first reported a position in FLXN in Q2 2017 and held it in 18 quarters. The position peaked at $57K in Q2 2018. 1 fund tracked by Wall St. Rank holds FLXN as of Q4 2021.
- Mark Sheptoff Financial Planning reported no remaining Flexion Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
- Mark Sheptoff Financial Planning sold 1,000 Flexion Therapeutics, Inc. shares in Q4 2021, an estimated $6K.
- Mark Sheptoff Financial Planning first reported a position in Flexion Therapeutics, Inc. in Q2 2017 and held it in 18 quarters.
- Mark Sheptoff Financial Planning's Flexion Therapeutics, Inc. position peaked at $57K in Q2 2018.
- 1 fund tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q4 2021.
Based on Mark Sheptoff Financial Planning's 13F filing for Q4 2021, filed 11 Feb 2022.